Bavarian Nordic’s CHIKV VLP Receives EMA’s Accelerated Assessment for Chikungunya
Shots:
- The CHMP has granted accelerated assessment to CHIKV VLP chikungunya vaccine, the MAA submission of which to the EMA is anticipated in H1’24 based on two P-III studies
- One of the P-III trial of CHIKV VLP (IM) vs PBO in healthy subjects (n=3,254; 12yrs.-64yrs.), depicted production of chikungunya neutralizing Ab in 98% of individuals after 22 days while in 47% & 97% of individuals after 8 & 15 days of vaccination respectively. Seroprotective Ab were found in 86% individuals after 6mos. of vaccination
- Another P-III study in healthy subjects (n=413; ≥65yrs.) demonstrated neutralizing Ab in 87% of subjects after 22 days of single vaccination. Seroprotective Ab were found in 82% of subjects at day 15
Ref: Bavarian Nordic | Image: Bavarian Nordic
Related News:- Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
